| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo … AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ... The lancet oncology 20 (2), 282-296, 2019 | 1485 | 2019 |
| Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ … Z Selmani, A Naji, I Zidi, B Favier, E Gaiffe, L Obert, C Borg, P Saas, ... Stem cells 26 (1), 212-222, 2008 | 1375 | 2008 |
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ... The lancet oncology 14 (1), 29-37, 2013 | 1335 | 2013 |
| Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial B Escudier, T Dorval, N Chaput, F André, MP Caby, S Novault, C Flament, ... Journal of translational medicine 3, 1-13, 2005 | 1333 | 2005 |
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer AF Sobrero, J Maurel, L Fehrenbacher, W Scheithauer, YA Abubakr, ... Journal of clinical oncology 26 (14), 2311-2319, 2008 | 1190 | 2008 |
| Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells F Chalmin, S Ladoire, G Mignot, J Vincent, M Bruchard, JP Remy-Martin, ... The Journal of clinical investigation 120 (2), 457-471, 2010 | 1118 | 2010 |
| Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised … T Conroy, JF Bosset, PL Etienne, E Rio, É François, N Mesgouez-Nebout, ... The Lancet Oncology 22 (5), 702-715, 2021 | 616 | 2021 |
| NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs C Borg, A Jalil, D Laderach, K Maruyama, H Wakasugi, S Charrier, ... Blood 104 (10), 3267-3275, 2004 | 439 | 2004 |
| Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 E Vacchelli, Y Ma, EE Baracco, A Sistigu, DP Enot, F Pietrocola, H Yang, ... Science 350 (6263), 972-978, 2015 | 432 | 2015 |
| Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression F Chalmin, G Mignot, M Bruchard, A Chevriaux, F Végran, A Hichami, ... Immunity 36 (3), 362-373, 2012 | 370 | 2012 |
| Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects C Borg, M Terme, J Taïeb, C Ménard, C Flament, C Robert, K Maruyama, ... The journal of clinical investigation 114 (3), 379-388, 2004 | 360 | 2004 |
| Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the … YJ Bang, YK Kang, DV Catenacci, K Muro, CS Fuchs, R Geva, H Hara, ... Gastric Cancer 22, 828-837, 2019 | 234 | 2019 |
| Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer B Guiu, JM Petit, F Bonnetain, S Ladoire, S Guiu, JP Cercueil, D Krausé, ... Gut 59 (3), 341-347, 2010 | 234 | 2010 |
| Natural killer cell IFN-γ levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor–bearing patients C Ménard, JY Blay, C Borg, S Michiels, F Ghiringhelli, C Robert, C Nonn, ... Cancer research 69 (8), 3563-3569, 2009 | 221 | 2009 |
| Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner T Mgrditchian, T Arakelian, J Paggetti, MZ Noman, E Viry, E Moussay, ... Proceedings of the National Academy of Sciences 114 (44), E9271-E9279, 2017 | 196 | 2017 |
| PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer M Dosset, TR Vargas, A Lagrange, R Boidot, F Végran, A Roussey, ... Oncoimmunology 7 (6), e1433981, 2018 | 189 | 2018 |
| Predictors of responses to immune checkpoint blockade in advanced melanoma N Jacquelot, MP Roberti, DP Enot, S Rusakiewicz, N Ternès, S Jegou, ... Nature communications 8 (1), 592, 2017 | 189 | 2017 |
| Role of STAT3 in CD4+ CD25+ FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity JR Pallandre, E Brillard, G Créhange, A Radlovic, JP Remy-Martin, ... The Journal of Immunology 179 (11), 7593-7604, 2007 | 181 | 2007 |
| Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study PA Philip, J Lacy, F Portales, A Sobrero, R Pazo-Cid, JLM Mozo, EJ Kim, ... The lancet Gastroenterology & hepatology 5 (3), 285-294, 2020 | 179 | 2020 |
| PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma A Asgarova, K Asgarov, Y Godet, P Peixoto, A Nadaradjane, ... Oncoimmunology 7 (5), e1423170, 2018 | 179 | 2018 |
